The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.
Avishay Sella
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; GlaxoSmithKline; Novartis; Pfizer
M. Dror Michaelson
Research Funding - Pfizer
Ewa M. Matczak
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ronit Simantov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Mariajose Lechuga
Disclosure not yet available
Xun Lin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Robert A. Figlin
Consultant or Advisory Role - Pfizer